Influence of systemic inflammation on the interpretation of response to antiplatelet therapy, monitored by PFA-100

Seminars in Thrombosis and Hemostasis

Volumn 31, Issue 4, 2005, Pages 416-419

  Ziegler, Sophie ^a   Alt, Elisabeth ^a   Brunner, Martin ^a   Speiser, Wolfgang ^a   Minar, Erich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acetylsalicylic acid; C reactive protein; Inflammation; Peripheral arterial occlusive disease; PFA 100; Platelet Function Analyzer System

Indexed keywords

ADRENALIN; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; COLLAGEN;

ANALYZER; ARTERY DISEASE; CONFERENCE PAPER; DRUG EFFICACY; DRUG MONITORING; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; C-REACTIVE PROTEIN; COLLAGEN; DIFFUSION; DRUG MONITORING; EPINEPHRINE; FEMALE; HUMANS; INFLAMMATION; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS;

EID: 25444473954     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-916676     Document Type: Conference Paper

References (27)

1. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000;36:110-114
2. Fiotti N, Giansante C, Ponte E, et al. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 1999;145:51-60
3. Li-Saw-Hee FL, Blann AD, Lip GJ. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic arterial fibrillation. Stroke 2000;31:828-833
4. Isaka N, Tanigawa T, Nishikawa M, Nakano T. High shear stress induced platelet aggregation (h-SIPA) and effects of antiplatelet therapy [in Japanese]. Nippon Rinsho 1998;56:2624-2629
5. Turner NA, Moake JL, Kamat SG, et al. Comparative real time effects on platelets adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIbIIIa. Circulation 1995;91:1354-1362
6. Homoncik M, Blann AD, Hollenstein U, Pernerstorfer T, Eichler HG, Jilma B. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 2000;111:1250-1252
7. Gralnik HR, McKeown LP, Wilson OM, Williams SB, Elin RJ. von Willebrand factor release induced by endotoxin. J Lab Clin Med 1989;113:118-122
8. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a) and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-2485
9. Langlois M, Duprez D, Delanghe J, Buyzere M, Clement DL. Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation 2001;103:1863-1868
10. Rossi E, Biasucci LM, Citterio F, et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 2002;105:800-803
11. Ortel T, James AH, Thames EH, Moore KD, Greenberg CS. Assessment of primary hemostasis by PFA-100 analysis in a tertiary care centre. Thromb Haemost 2000;84:93-97
12. von Pape KW, Aland E, Bohner J. Platelet function analysis with PFA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample. Thromb Res 2000;98;295-299
13. Favaloro EJ, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen von Willebrand's disease and other disorders. Am J Hematol 1999;62:165-174
14. Albert MA, Ridker PM. The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep 1999;1:99-104
15. McKenzie M, Gurbel PA, Levine DJ, Serebruany VL. Clinical utility of available methods for determining platelet function. Cardiology 1999;92:240-247
16. Ziegler S, Alt E, Brunner M, Speiser W, Minar E. Influence of systemic inflammation on efficiency of antiplatelet therapy in PAOD patients. Ann Hematol 2004;83:92-94
17. Camici M. C-reactive protein, atherosclerosis and cardiovascular disease. An update. Minerva Cardioangiol 2002;50:327-331
18. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997;26:517-538
19. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000;83:316-321
20. Silva JA, White CJ. Plaque instability in peripheral vessels. Prog Cardiovasc Dis 2002;44:429-436
21. Sestito A, Sciahbasi A, Landolfi R, Maseri A. A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100); reproducibility and effects of sex and age. Cardiologia 1999;44:661-665
22. van Genderen PJ, van Vliet HH, Prins FJ, et al. Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma. Ann Hematol 1997;75:215-220
23. Pernerstorfer T, Eichler HG, Stohlawetz P, Speiser W, Jilma B. Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand factor levels in healthy men. Atherosclerosis 2001;155:389-393
24. Kaplan RC, Frishman WH. Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. Heart Dis 2001;3:326-332
25. Cheng TO. Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects [abstract]. Clin Cardiol 1999;22:A27
26. Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation 2002;105:2600-2604
27. Guarnieri G. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 1999;145:51-60